MoonLake Immunotherapeutics
MLTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001821586
In the last 90 days, MoonLake Immunotherapeutics insiders filed 0 open-market purchases and 5 sales; 172 institutions reported holding it in 13F filings for Q2 2026, worth $1.43B in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding MoonLake Immunotherapeutics changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Of which not filed for Q4 2023 | Q4 2023 | Change |
|---|---|---|---|---|
| Holders | 118 | 2 | 125 | +9 |
| Shares | 56.3M | 64.3K | 59.3M | +3.07M (+5.5%) |
| Value | $3.21B | $3.67M | $3.53B | +$322.1M (+10.0%) |
2 institutions that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (37)
Institutions that held MoonLake Immunotherapeutics at the end of Q4 2023 but not at the end of Q3 2023.
Sold out (28)
Institutions that held MoonLake Immunotherapeutics at the end of Q3 2023 and filed for Q4 2023 without it.
Not filed for Q4 2023 yet (2)
Institutions that held MoonLake Immunotherapeutics at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| CHI Advisors LLC | 60,000 | $3.42M |
| First Republic Investment Management, Inc. | 4,310 | $245.7K |